HWEL

SC 13G/A - Healthwell Acquisition Corp. I (0001845013) (Subject)

SC 13G/A - Healthwell Acquisition Corp. I (0001845013) (Subject)

SC 13G/A - Healthwell Acquisition Corp. I (0001845013) (Subject)

15-12G - Healthwell Acquisition Corp. I (0001845013) (Filer)

25-NSE - Healthwell Acquisition Corp. I (0001845013) (Subject)

8-K/A - Healthwell Acquisition Corp. I (0001845013) (Filer)

8-K - Healthwell Acquisition Corp. I (0001845013) (Filer)

Healthwell Acquisition Corp. I ("Healthwell") (NASDAQ:HWEL) announced today that (i) its previously announced special meeting of stockholders that was scheduled for December 4, 2023 has been cancelled, and that it has withdrawn from consideration by Healthwell's stockholders the proposals set forth in Heatlhwell's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2023 and (ii) it intends instead to liquidate.The board of directors of Healthwell (the "Board") has determined to (i) cease all operations except for the purpose of winding up as soon as practicable, (ii) as promptly as reasonably possible redeem the shares

Healthwell Acquisition Corp. I ("Healthwell") (NASDAQ:HWEL) announced today that (i) its previously announced special meeting of stockholders that was scheduled for December 4, 2023 has been cancelled, and that it has withdrawn from consideration by Healthwell's stockholders the proposals set forth in Heatlhwell's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2023 and (ii) it intends instead to liquidate. The board of directors of Healthwell (the "Board") has determined to (i) cease all operations except for the purpose of winding up as soon as practicable, (ii) as promptly as reasonably possible redeem the sh

DEF 14A - Healthwell Acquisition Corp. I (0001845013) (Filer)

425 - Healthwell Acquisition Corp. I (0001845013) (Subject)

8-K - Healthwell Acquisition Corp. I (0001845013) (Filer)

Healthwell Acquisition Corp. I ("Healthwell") (NASDAQ:HWEL) announced today that its previously announced Business Combination Agreement in connection with its planned business combination with Starton Therapeutics, Inc. ("Starton") was terminated by Starton. The conditions to the closing of the initial business combination were not satisfied or waived by the outside date of November 3, 2023. As a result, Healthwell will seek an alternative business combination. About Healthwell Healthwell is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase,

Starton Therapeutics Inc. ("Starton" or "the Company"), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced that it notified Healthwell Acquisition Corp. I (NASDAQ:HWEL) ("Healthwell") today that the Company had elected to terminate the business combination agreement among Starton, Healthwell and the other parties thereto dated as of April 27, 2023, as amended (the "Combination Agreement"), effective immediately. The conditions to the closing of the initial business combination and subsequent amendments were not satisfied or waived by the outside date of November 3 2023 (the "Termination"). As a

PRE 14A - Healthwell Acquisition Corp. I (0001845013) (Filer)

425 - Healthwell Acquisition Corp. I (0001845013) (Subject)

8-K - Healthwell Acquisition Corp. I (0001845013) (Filer)

Healthwell Acquisition Has postponed until further announcement the date of the special meeting of the Company's stockholders to approve its proposed business combination with Starton Therapeutics, Inc. ("Starton") and related transactions that had been scheduled for 10:00 a.m. Eastern Time on October 25, 2023.

Healthwell Acquisition Corp. I ("Healthwell," "HWEL" or the "Company") (NASDAQ:HWEL) announced today that it has postponed until further announcement the date of the special meeting of the Company's stockholders (the "Meeting") to approve its proposed business combination with Starton Therapeutics, Inc. ("Starton") and related transactions that had been scheduled for 10:00 a.m. Eastern Time on October 25, 2023. At the Meeting, the stockholders will vote on the proposals set forth in Healthwell's proxy statement/prospectus dated October 2, 2023 and filed with the Securities and Exchange Commission to approve the business combination with Starton and related proposals described therein (colle

425 - Healthwell Acquisition Corp. I (0001845013) (Subject)

8-K - Healthwell Acquisition Corp. I (0001845013) (Filer)

Healthwell Acquisition Corp. I ("Healthwell," "HWEL" or the "Company") (NASDAQ:HWEL) announced today that it has postponed the date of the special meeting of the Company's stockholders (the "Meeting") to approve its proposed business combination with Starton Therapeutics, Inc. ("Starton") and related transactions from the originally scheduled date of October 19, 2023. The new Meeting time and date will be 10:00 a.m. Eastern Time on October 25, 2023 and will be held virtually. At the Meeting, the stockholders will vote on the proposals set forth in Healthwell's proxy statement/prospectus dated October 2, 2023 and filed with the Securities and Exchange Commission to approve the business combi

Dosing comes three weeks after the first site opened Full enrollment of six patients is expected to take 10 months, conducted in up to three clinical sites Multiple readings for safety and efficacy are expected during the next 6 to 18 months Starton Therapeutics Inc. ("Starton" or "the Company"), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced the dosing of the first patient in the STAR-LLD Phase 1b clinical trial, which will assess the safety, efficacy and pharmacokinetics of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) for the treatment of multiple m

DEFM14A - Healthwell Acquisition Corp. I (0001845013) (Filer)